An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer. Adam J.

CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.

A patient recounts sudden vision changes leading to brain tumor surgery and a switch from immunotherapy to targeted therapy ...

Immune checkpoint inhibitors (ICIs) have become a treatment option for many patients with advanced melanoma. Still, the chances of long-term success of ICIs for advanced melanoma remain only about 50% ...

Scientists from the Moffitt Cancer Center say they now have a better understanding why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings ...

NEW YORK--(BUSINESS WIRE)--Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation tumor-infiltrating lymphocyte (“TIL”) therapy and viral immunotherapy designed ...

Until recently, solid tumors — which make up 90% of cancer diagnoses — had no cell therapy. However, that changed in 2024, when the FDA approved a treatment from Iovance Biotherapeutics for advanced ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. It’s not common for cancer surgeons to turn their focus ...

BURTON UPON TRENT, England--(BUSINESS WIRE)--Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company acknowledges the presentation of results from the ...

- TIL Therapy Emerging As Unexplored Billion Dollar Market Says Kuick Research NEW DELHI, April 15, 2021 /PRNewswire/ -- "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & ...

RICHMOND, Va. (WRIC) — Virginia Commonwealth University’s (VCU) Massey Comprehensive Cancer Center is the first and only authorized treatment center in the commonwealth to offer a special type of ...